ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

TACI receptor-IgG Fc fragment fusion protein

Also written as “Atacicept”, “Atacicept 150 mg” and “Atacicept 75 mg”.

Its studies are mostly in Glomerulonephritis, IGA · Lupus Erythematosus, Systemic · Lupus Nephritis · Arthritis, Rheumatoid · Multiple Sclerosis, led by 2 companies.

Drug pageTACI receptor-IgG Fc fragment fusion protein: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 11, 200718 company-led studies, 4 open or runningNext primary completion: Nov 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck KGaA, Darmstadt, Germanyits history only130 open or runningphase 3since Dec 11, 2007Jan 30, 2007none ahead
Vera Therapeuticsits history only54 open or runningphase 3since Jan 11, 2021Jan 11, 2021Nov 2027phase 2 · NCT06983028

Also a collaborator on its studies: Bristol-Myers Squibb.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Jan 30, 2007.

  1. Feb 15, 2008Phase 2 study in Optic NeuritisMerck KGaA, Darmstadt, Germany · NCT00624468 · 34 enrolled · United States, Australia, Belgium and more
  2. Feb 15, 2008Phase 3 study in Lupus Erythematosus, SystemicMerck KGaA, Darmstadt, Germany · NCT00624338 · 461 enrolled · United States, Argentina, Australia and more
  3. Mar 21, 2008Phase 2 study in Relapsing Multiple SclerosisMerck KGaA, Darmstadt, Germany · NCT00642902 · 255 enrolled · United States, Australia, Austria and more
  4. Apr 21, 2008Phase 2 study in Arthritis, RheumatoidMerck KGaA, Darmstadt, Germany · NCT00664521 · 27 enrolled · France, Netherlands, Sweden and more
  5. Feb 26, 2009Phase 2 study in Relapsing Multiple SclerosisMerck KGaA, Darmstadt, Germany · NCT00853762 · 74 enrolled · United States, Australia, Belgium and more
  6. Jun 7, 2011Phase 1 study in Lupus NephritisMerck KGaA, Darmstadt, Germany · NCT01369628 · 1 enrolled · United States
  7. Sep 22, 2011Phase 2 study in Lupus Erythematosus, SystemicMerck KGaA, Darmstadt, Germany · NCT01440231
  8. Oct 24, 2013Phase 2 study in Lupus Erythematosus, SystemicMerck KGaA, Darmstadt, Germany · NCT01972568 · 306 enrolled · United States, Argentina, Brazil and more
  9. Feb 21, 2014Phase 2 study in Lupus Erythematosus, SystemicMerck KGaA, Darmstadt, Germany · NCT02070978 · 253 enrolled · United States, Argentina, Brazil and more
  10. Jun 16, 2016Phase 2 study in Glomerulonephritis, IGAMerck KGaA, Darmstadt, Germany · NCT02808429 · 16 enrolled · United States, Japan, United Kingdom
  11. Jan 11, 2021Vera Therapeutics’ first study: phase 3 study in Glomerulonephritis, IGANew to Vera TherapeuticsVera Therapeutics · NCT04716231 · 428 enrolled · United States
  12. Nov 2, 2022Phase 3 study in Lupus NephritisVera Therapeutics · NCT05609812 · United States, Puerto Rico, Spain
  13. Oct 3, 2024Phase 2 study in Glomerulonephritis, IGAVera Therapeutics · NCT06674577 · 750 planned · United States
  14. May 13, 20252 phase 2 studiesVera Therapeutics · NCT07020923, NCT06983028

Ahead

  1. Nov 2027Primary completion: phase 2 study in Nephrotic SyndromeVera Therapeutics · NCT06983028
  2. May 21, 2031Primary completion: phase 2 study in Glomerulonephritis, IGAVera Therapeutics · NCT06674577

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07020923Glomerulonephritis, IGA · United States2Active, not recruitingVera TherapeuticsSep 22, 202690
NCT06983028Nephrotic Syndrome · United States2RecruitingVera TherapeuticsNov 2027250
NCT06674577Glomerulonephritis, IGA · United States2By invitationVera TherapeuticsMay 21, 2031750
NCT05609812Lupus Nephritis · United States, Puerto Rico, Spain3WithdrawnVera TherapeuticsMar 15, 20260
NCT04716231Glomerulonephritis, IGA · United States3Active, not recruitingVera TherapeuticsMay 15, 2025428
NCT02808429Glomerulonephritis, IGA · United States, Japan, United Kingdom2TerminatedMerck KGaA, Darmstadt, GermanyFeb 7, 202016
NCT02070978Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more2TerminatedMerck KGaA, Darmstadt, GermanyApr 5, 2016253
NCT01972568Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more2CompletedMerck KGaA, Darmstadt, GermanyApr 2016306
NCT01440231Lupus Erythematosus, Systemic2WithdrawnMerck KGaA, Darmstadt, GermanyAug 20130
NCT01369628Lupus Nephritis · United States1TerminatedMerck KGaA, Darmstadt, GermanyNov 20111
NCT00853762Relapsing Multiple Sclerosis · United States, Australia, Belgium and more2TerminatedMerck KGaA, Darmstadt, GermanySep 200974
NCT00664521Arthritis, Rheumatoid · France, Netherlands, Sweden and more2CompletedMerck KGaA, Darmstadt, GermanyOct 201027
NCT00642902Relapsing Multiple Sclerosis · United States, Australia, Austria and more2TerminatedMerck KGaA, Darmstadt, GermanySep 2009255
NCT00624468Optic Neuritis · United States, Australia, Belgium and more2TerminatedMerck KGaA, Darmstadt, GermanySep 200934
NCT00624338Lupus Erythematosus, Systemic · United States, Argentina, Australia and more3CompletedMerck KGaA, Darmstadt, GermanyApr 2012461
NCT00595413Arthritis, Rheumatoid · United States, Germany2CompletedMerck KGaA, Darmstadt, GermanyOct 2009311
NCT00573157Lupus Nephritis · United States, Czech Republic, Malaysia and more3TerminatedMerck KGaA, Darmstadt, GermanyApr 20096
NCT00430495Arthritis, Rheumatoid · United States, Canada2CompletedMerck KGaA, Darmstadt, GermanySep 2009256

How it is read

Names in the registry

  • “Atacicept”, 19 entries
  • “Atacicept 150 mg”, 7 entries
  • “Atacicept 75 mg”, 4 entries
  • “Atacicept 25 mg”, 2 entries
  • “Atacicept: with loading dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.